



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

WNK-IN-11-d₃

Cat. No.:	HY-112094S
CAS No.:	2123483-49-6
Molecular Formula:	C ₂₁ H ₁₈ D ₃ Cl ₂ N ₅ OS
Molecular Weight:	465.41
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (214.86 mM)
 DMSO : ≥ 100 mg/mL (214.86 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1486 mL	10.7432 mL	21.4864 mL
	5 mM		0.4297 mL	2.1486 mL	4.2973 mL
	10 mM		0.2149 mL	1.0743 mL	2.1486 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

WNK-IN-11-d₃ is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d₃ is effective at regulating cardiovascular homeostasis^[1].

IC₅₀ & Target

WNK^[1]

In Vivo

WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability^[1].
 WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice^[1].
 WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg^[1].
 WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague–Dawley rats ^[1]
Dosage:	1.5 mg/kg
Administration:	P.o.
Result:	Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
Animal Model:	FVB mice ^[1]
Dosage:	30 mg/kg
Administration:	P.o.
Result:	Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.
Animal Model:	FVB mice ^[1]
Dosage:	0~100 mg/kg
Administration:	P.o.
Result:	Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.

REFERENCES

[1]. Yamada K, Levell J, Yoon T, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017;60(16):7099-7107.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA